Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 2
2005 1
2006 1
2007 3
2008 2
2009 3
2010 1
2011 2
2012 4
2013 4
2014 4
2015 4
2016 3
2017 5
2018 15
2019 9
2020 5
Text availability
Article attribute
Article type
Publication date

Search Results

65 results
Results by year
Filters applied: . Clear all
Page 1
Significance of intrinsic breast cancer subtypes on the long-term prognosis after neoadjuvant chemotherapy.
Goto W, Kashiwagi S, Takada K, Asano Y, Takahashi K, Fujita H, Takashima T, Tomita S, Hirakawa K, Ohira M. Goto W, et al. Among authors: takahashi k. J Transl Med. 2018 Nov 9;16(1):307. doi: 10.1186/s12967-018-1679-0. J Transl Med. 2018. PMID: 30413161 Free PMC article.
Clinical Outcomes of Recombinant Human-soluble Thrombomodulin Treatment for Disseminated Intravascular Coagulation in Solid Tumors.
Kashiwagi S, Asano Y, Takahashi K, Shibutani M, Amano R, Tomita S, Hirakawa K, Ohira M. Kashiwagi S, et al. Among authors: takahashi k. Anticancer Res. 2019 May;39(5):2259-2264. doi: 10.21873/anticanres.13342. Anticancer Res. 2019. PMID: 31092417 Review.
Predictive value of lymphocyte-to-monocyte ratio in the preoperative setting for progression of patients with breast cancer.
Goto W, Kashiwagi S, Asano Y, Takada K, Takahashi K, Hatano T, Takashima T, Tomita S, Motomura H, Hirakawa K, Ohira M. Goto W, et al. Among authors: takahashi k. BMC Cancer. 2018 Nov 19;18(1):1137. doi: 10.1186/s12885-018-5051-9. BMC Cancer. 2018. PMID: 30453914 Free PMC article.
Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer.
Takada K, Kashiwagi S, Goto W, Asano Y, Takahashi K, Takashima T, Tomita S, Ohsawa M, Hirakawa K, Ohira M. Takada K, et al. Among authors: takahashi k. J Transl Med. 2018 Apr 3;16(1):86. doi: 10.1186/s12967-018-1460-4. J Transl Med. 2018. PMID: 29615076 Free PMC article.
The Effects of Eribulin on Breast Cancer Microenvironment Identified Using Eribulin-resistant Breast Cancer Cell Lines.
Goto W, Kashiwagi S, Asano Y, Takada K, Takahashi K, Fujita H, Takashima T, Shibutani M, Amano R, Tomita S, Hirakawa K, Ohira M. Goto W, et al. Among authors: takahashi k. Anticancer Res. 2019 Aug;39(8):4031-4041. doi: 10.21873/anticanres.13559. Anticancer Res. 2019. PMID: 31366485
Verification of the effects of calcium channel blockers on the immune microenvironment of breast cancer.
Takada K, Kashiwagi S, Asano Y, Goto W, Takahashi K, Fujita H, Takashima T, Tomita S, Hirakawa K, Ohira M. Takada K, et al. Among authors: takahashi k. BMC Cancer. 2019 Jun 24;19(1):615. doi: 10.1186/s12885-019-5828-5. BMC Cancer. 2019. PMID: 31234828 Free PMC article.
Clinical Evaluation of Dynamic Monitoring of Neutrophil-to-lymphocyte and Platelet-to-lymphocyte Ratios in Primary Endocrine Therapy for Advanced Breast Cancer.
Takada K, Kashiwagi S, Asano Y, Goto W, Takahashi K, Shibutani M, Amano R, Takashima T, Tomita S, Hirakawa K, Ohira M. Takada K, et al. Among authors: takahashi k. Anticancer Res. 2019 Oct;39(10):5581-5588. doi: 10.21873/anticanres.13752. Anticancer Res. 2019. PMID: 31570453
Risk of malignant lymphoma in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs and methotrexate
.
Inose R, Hosomi K, Takahashi K, Yokoyama S, Takada M. Inose R, et al. Among authors: takahashi k. Int J Clin Pharmacol Ther. 2019 Feb;57(2):63-72. doi: 10.5414/CP203341. Int J Clin Pharmacol Ther. 2019. PMID: 30526810
Novel evaluation scale for QOL (QOL-ACD-BP) in preoperative chemotherapy for breast cancer.
Takada K, Kashiwagi S, Goto W, Asano Y, Takahashi K, Morisaki T, Takashima T, Tomita S, Hirakawa K, Ohira M. Takada K, et al. Among authors: takahashi k. J Cancer Res Clin Oncol. 2018 Aug;144(8):1547-1559. doi: 10.1007/s00432-018-2670-0. Epub 2018 May 19. J Cancer Res Clin Oncol. 2018. PMID: 29779135 Free PMC article.
Mesenchymal-epithelial Transition and Tumor Vascular Remodeling in Eribulin Chemotherapy for Breast Cancer.
Kashiwagi S, Asano Y, Goto W, Takada K, Takahashi K, Hatano T, Tanaka S, Takashima T, Tomita S, Motomura H, Ohsawa M, Hirakawa K, Ohira M. Kashiwagi S, et al. Among authors: takahashi k. Anticancer Res. 2018 Jan;38(1):401-410. doi: 10.21873/anticanres.12236. Anticancer Res. 2018. PMID: 29277801
65 results
Jump to page
Feedback